Once-Daily Atomoxetine for Adult Attention-Deficit/Hyperactivity Disorder: A 6-Month, Double-Blind Trial
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
This randomized, double-blind, placebo-controlled, 6-month trial examined the efficacy and safety of once-daily morning-dosed atomoxetine in adult patients with attention-deficit/hyperactivity disorder (ADHD) and the efficacy of atomoxetine in ameliorating symptoms through the evening hours. Patients received once-daily atomoxetine (n = 250) or placebo (n = 251) in the morning for approximately 6 months. The efficacy measures included the Adult ADHD Investigator Symptom Rating Scale (AISRS), Conners' Adult ADHD Rating Scale-Investigator Rated: Screening Version, Clinical Global Impressions-ADHD-Severity of Illness, and Adult ADHD Quality of Life Scale. Overall, 94 patients randomized to atomoxetine and 112 patients randomized to placebo completed the study. On the AISRS total score, Conners' Adult ADHD Rating Scale-Investigator Rated: Screening Version evening index total score, Clinical Global Impressions-ADHD-Severity of Illness score, and Adult ADHD Quality of Life Scale total score, atomoxetine was statistically superior to placebo at the 10-week and 6-month time points. From the visitwise analysis, the mean (SD) AISRS total scores for atomoxetine decreased from 38.2 (7.5) at baseline to 21.4 (12.3) at the 6-month end point compared with 38.6 (7.0) to 25.8 (13.2) for placebo (P = 0.035). Nausea, dry mouth, fatigue, decreased appetite, urinary hesitation, and erectile dysfunction were the treatment-emergent adverse events reported significantly more often with atomoxetine. Discontinuations due to adverse events were 17.2% and 5.6% for atomoxetine and placebo, respectively (P < 0.001). Once-daily morning-dosed atomoxetine is efficacious for treating ADHD in adults when measured 10 weeks and 6 months after initiating treatment. Atomoxetine demonstrated significant efficacy that continued into the evening. Adverse events were similar to previous trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.716 · Cited by 3,886
Self-citationKESSLER, R. C., ADLER, L., AMES, M., DEMLER, O., FARAONE, S., HIRIPI, E., HOWES, M. J., JIN, R., SECNIK, K., SPENCER, T., et al. (2005) · Psychological Medicine · doi:10.1017/s0033291704002892 · Cited by 3,452
Self-citationAtomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01671-2 · Cited by 790
Self-citationWENDER, P. H., WOLF, L. E., & WASSERSTEIN, J. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb05770.x · Cited by 498
Kelsey, D. K., Sumner, C. R., Casat, C. D., Coury, D. L., Quintana, H., Saylor, K. E., Sutton, V. K., Gonzales, J., Malcolm, S. K., Schuh, K. J., et al. (2004) · Pediatrics · doi:10.1542/peds.114.1.e1 · Cited by 464 · cited 1×
“Efficacy in adults that can be measured into the evening extends similar results found in a pediatric population.(9) This finding is particularly meaningful because adults typically have responsibilities for self and others in the evenings.”
ResultSelf-citationSpencer, T., Biederman, J., Wilens, T., Doyle, R., Surman, C., Prince, J., Mick, E., Aleardi, M., Herzig, K., & Faraone, S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.043 · Cited by 385
Self-citationDiagnosis and evaluation of adults with attention-deficit/hyperactivity disorder
Adler, L., & Cohen, J. (2004) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2003.12.003 · Cited by 290
Self-citationA Clinical Perspective of Attention-Deficit/Hyperactivity Disorder Into Adulthood
Wilens, T. E., & Dodson, W. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1003 · Cited by 274
Biederman, J., Mick, E., Surman, C., Doyle, R., Hammerness, P., Harpold, T., Dunkel, S., Dougherty, M., Aleardi, M., & Spencer, T. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.011 · Cited by 267
Self-citationBrod, M., Johnston, J., Able, S., & Swindle, R. (2006) · Quality of Life Research · doi:10.1007/s11136-005-8325-z · Cited by 200
Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders
Wilens, T. E., Adler, L. A., Weiss, M. D., Michelson, D., Ramsey, J. L., Moore, R. J., Renard, D., Brady, K. T., Trzepacz, P. T., Schuh, L. M., et al. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.02.009 · Cited by 171
Self-citationWeisler, R. H., Biederman, J., Spencer, T. J., Wilens, T. E., Faraone, S. V., Chrisman, A. K., Read, S. C., & Tulloch, S. J. (2006) · CNS Spectrums · doi:10.1017/s1092852900013687 · Cited by 158
Self-citationDodson, W. W. (2005) · Journal of Clinical Psychology · doi:10.1002/jclp.20122 · Cited by 88
Spencer, T. J., Kratochvil, C. J., Sangal, R. B., Saylor, K. E., Bailey, C. E., Dunn, D. W., Geller, D. A., Casat, C. D., Lipetz, R. S., Jain, R., et al. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.0100 · Cited by 75 · cited 1×
“This is consistent with findings in children that demonstrate more pronounced weight loss early in treatment, with weight no longer significantly different from that expected by the end of the third year of treatment.(22) Although this study found significant effects into the evening, several limitations should be con…”
ResultSelf-citationResponsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL)
Matza, L. S., Johnston, J. A., Faries, D. E., Malley, K. G., & Brod, M. (2007) · Quality of Life Research · doi:10.1007/s11136-007-9254-9 · Cited by 69 · cited 1×
“In addition, changes in CAARS-Inv:SV scores were similar to changes in an ADHD quality of life measure, the AAQoL, in a prior atomoxetine adult ADHD trial.(23) It should also be noted that the primary outcome measure in this study, the AISRS, is a clinician-administered rating scale.”
Result
Research works printed but not linked: 6
- Faraone, 2007, ADHD in adults-a familiar disease with unfamiliar challenges., CNS Spectr, 12, 14, 10.1017/S1092852900003801 · DOI
- Adler, 2006, Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD., Ann Clin Psychiatry, 18, 107, 10.1080/10401230600614603 · DOI · Paper page
- Adler, 2005, Training raters to assess adult ADHD: reliability of ratings., J Atten Disord, 8, 121, 10.1177/1087054705277168 · DOI · Paper page
- Brod, 2005, Conceptualization and assessment of quality of life for adults with attention-deficit/hyperactivity disorder., Prim Psychiatry, 12, 58
- Adler, 2002, Management of ADHD in adults., J Clin Psychiatry, 63, 29
- Adler, 2008, Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study., J Atten Disord, 12, 248, 10.1177/1087054708316250 · DOI · Paper page
Cited by
Kooij, S. J., Bejerot, S., Blackwell, A., Caci, H., Casas-Brugué, M., Carpentier, P. J., Edvinsson, D., Fayyad, J., Foeken, K., Fitzgerald, M., et al. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-67 · Cited by 928
“Atomoxetine is usually considered the second line treatment, followed by other non-stimulants like bupropion, guanfacine, modafinil and tricyclic antidepressents, based on efficacy outcomes in controlled studies in different age groups [239,261-264].”
College Students With ADHD: Current Status and Future Directions
DuPaul, G. J., Weyandt, L. L., O'Dell, S. M., & Varejao, M. (2009) · Journal of Attention Disorders · doi:10.1177/1087054709340650 · Cited by 488
Attention-deficit/hyperactivity disorder
Faraone, S. V., Bellgrove, M. A., Brikell, I., Cortese, S., Hartman, C. A., Hollis, C., Newcorn, J. H., Philipsen, A., Polanczyk, G. V., Rubia, K., et al. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00495-0 · Cited by 355
Fredriksen, M., Halmøy, A., Faraone, S. V., & Haavik, J. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.07.016 · Cited by 173
Adler, L. A., Liebowitz, M., Kronenberger, W., Qiao, M., Rubin, R., Hollandbeck, M., Deldar, A., Schuh, K., & Durell, T. (2009) · Depression and Anxiety · doi:10.1002/da.20549 · Cited by 176
Self-citation
Metadata
- Authors
- Adler, L. A., Spencer, T., Brown, T. E., Holdnack, J., Saylor, K., Schuh, K., Trzepacz, P. T., Williams, D. W., & Kelsey, D.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2009-02
- Volume
- 29
- Issue
- 1
- Pages
- 44-50
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2077367843
- Cited by
- 142
- References
- 15
- FWCI
- 11.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.